产品详情
简单介绍：
Anti-HSPABP/HIP/HSC70 Interacting Protein HIP抗体产品质量稳定，实验效果明显，货期快，价格优惠，欢迎垂询订购！我公司长期供应**组化抗体、WB抗体、**组化试剂盒和抗体试验所需全部相关试剂、荧光标记抗体、单克隆抗体、多克隆抗体、各种标记的二抗IgG/IgM/IgD/IgA等科研实验抗体。Anti-HSPABP/HIP/HSC70 Interacting Protein HIP抗体用于**组化实验,WB实验,相应的标记抗体有HRP标记抗体,FITC标记,BIO等。
详情介绍：
Rabbit Anti-HSPABP/HIP/HSC70 Interacting Protein HIP
Cat. Number:
Anti-HSPABP/HIP/HSC70 Interacting Protein HIP抗体KL-11271R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Hip (HSP70-interacting protein), also known as ST13 (suppression of tumorigenicity protein 13), is one of several co-chaperones that
Anti-HSPABP/HIP/HSC70 Interacting Protein HIP抗体regulate activities of the HSP70 chaperone family (1,2). The homo-oligomeric protein Hip cooperates with HSP70 in protein folding by stabilizing the ADP-bound state of HSP70. Hip directly binds to the ATPase domain of HSP70 when it is converted to the ADP-bound state by proteins of the HSP40 family (3). By collaborating with other positive co-factors such as HSP40 and Hop, or competing with negative co-factors such as Bag1, Hip may facilitate the chaperone function of HSP70 in protein folding and repair, and in controlling the activity of regulatory proteins such as steroid receptors and various regulators of proliferation or apoptosis (4-8).
Also known as:
AAG 2; AAG2; Aging associated protein 2;
Anti-HSPABP/HIP/HSC70 Interacting Protein HIP抗体F10A1_HUMAN; FAM10A1; FAM10A4; FLJ27260; Heat shock 70kD protein binding protein; HIP; HOP; Hsc70 interacting protein; Hsc70-interacting protein; Hsp70 interacting protein; HSPABP 1; HSPABP; HSPABP1; MGC129952; OTTHUMP00000028873; P48 antibody PRO0786; Progesterone receptor associated p48 protein; Progesterone receptor-associated p48 protein; Protein FAM10A1; Putative tumor suppressor ST13; Renal carcinoma antigen NY REN 33; Renal carcinoma antigen NY-REN-33; SNC 6; SNC6; ST 13; ST13; Suppression of tumorigenicity 13; Suppression of tumorigenicity 13 (c
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, .
Anti-HSPABP/HIP/HSC70 Interacting Protein HIP抗体
●
Immunogen: KLH conjugated synthetic peptide derived from human HSPABP.
●
Predicted Molecular Weight: 41kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-HSPABP/HIP/HSC70 Interacting Protein HIP抗体
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-HSPABP/HIP/HSC70 Interacting Protein HIP抗体
Optimal working dilutions must be determined by the end user.
kl166Ra01 胃蛋白酶原C(PGC)多克隆抗体 Polyclonal Antibody to Pepsinogen C (PGC)
kl167Hu01 前列腺素E合酶(PTGES)多克隆抗体 Polyclonal Antibody to Prostaglandin E Synthase, Microsomal (PTGES)
kl168Hu01 前列腺酸性磷酸酶(ACP3)多克隆抗体 Polyclonal Antibody to Acid Phosphatase 3, Prostatic (ACP3)
kl171Hu01 安眠蛋白1α(MEP1α)多克隆抗体 Polyclonal Antibody to Meprin A Alpha (MEP1a)
kl172Bo01 血小板因子4(PF4)多克隆抗体 Polyclonal Antibody to Platelet Factor 4 (PF4)
kl172Cp01 血小板因子4(PF4)多克隆抗体 Polyclonal Antibody to Platelet Factor 4 (PF4)
kl172Hu01 血小板因子4(PF4)多克隆抗体 Polyclonal Antibody to Platelet Factor 4 (PF4)
kl172Mu01 血小板因子4(PF4)多克隆抗体 Polyclonal Antibody to Platelet Factor 4 (PF4)
kl172Po01 血小板因子4(PF4)多克隆抗体 Polyclonal Antibody to Platelet Factor 4 (PF4)
kl172Ra01 血小板因子4(PF4)多克隆抗体 Polyclonal Antibody to Platelet Factor 4 (PF4)
kl172Rb51 血小板因子4(PF4)多克隆抗体 Polyclonal Antibody to Platelet Factor 4 (PF4)
kl174Hu01 髓鞘型脂肪酸结合蛋白(FABP8)多克隆抗体 Polyclonal Antibody to Fatty Acid Binding Protein 8, Myelin (FABP8)
kl175Hu01 干扰素α4(IFNα4)多克隆抗体 Polyclonal Antibody to Interferon Alpha 4 (IFNa4)
kl177Hu01 酸性葡糖苷酶α(GαA)多克隆抗体 Polyclonal Antibody to Glucosidase Alpha, Acid (GaA)
kl179Hu01 干扰素α2(IFNα2)多克隆抗体 Polyclonal Antibody to Interferon Alpha 2 (IFNa2)
kl181Ca01 中性粒细胞弹性蛋白酶(ELA2)多克隆抗体 Polyclonal Antibody to Elastase 2, Neutrophil (ELA2)
kl181Hu01 中性粒细胞弹性蛋白酶(ELA2)多克隆抗体 Polyclonal Antibody to Elastase 2, Neutrophil (ELA2)
